Bosh sahifaMYGN • NASDAQ
add
Myriad Genetics Inc
14,28 $
Seans yopilganidan keyin:(0,00%)0,00
14,28 $
Yopilgan:13-yan, 16:02:41 (GMT-5) · USD · NASDAQ · Ogohlantirish
Yopilish kursi
14,83 $
Kunlik diapazon
14,01 $ - 14,93 $
Yillik diapazon
12,87 $ - 29,30 $
Bozor kapitalizatsiyasi
1,30 mlrd USD
Oʻrtacha hajm
991,38 ming
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
NASDAQ
Bozor yangiliklari
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
(USD) | sen, 2024info | Y/Y qiyosi |
---|---|---|
Daromad | 213,30 mln | 11,15% |
Joriy xarajat | 167,60 mln | 4,68% |
Sof foyda | -22,10 mln | 63,95% |
Sof foyda marjasi | -10,36 | 67,56% |
Har bir ulushga tushum | 0,06 | 300,00% |
EBITDA | -2,20 mln | 87,36% |
Amaldagi soliq stavkasi | -4,25% | — |
Balans
Jami aktivlari
Jami passivlari
(USD) | sen, 2024info | Y/Y qiyosi |
---|---|---|
Naqd pul va qisqa investitsiyalar | 99,90 mln | 15,76% |
Jami aktivlari | 1,08 mlrd | -5,90% |
Jami passivlari | 349,60 mln | -24,93% |
Umumiy kapital | 731,70 mln | — |
Tarqatilgan aksiyalar | 91,04 mln | — |
Narxi/balansdagi bahosi | 1,84 | — |
Aktivlardan daromad | -4,11% | — |
Kapitaldan daromad | -5,06% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
(USD) | sen, 2024info | Y/Y qiyosi |
---|---|---|
Sof foyda | -22,10 mln | 63,95% |
Operatsiyalardan naqd pul | 700,00 ming | 103,17% |
Sarmoyadan naqd pul | 7,50 mln | 400,00% |
Moliyadan naqd pul | -3,10 mln | -24,00% |
Naqd pulning sof oʻzgarishi | 8,60 mln | 131,05% |
Boʻsh pul | 16,28 mln | 148,95% |
Haqida
Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new products that assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to a particular drug therapy, assess a patient's risk of disease progression and disease recurrence, and measure disease activity. Wikipedia
Tashkil etilgan
1991
Sayt
Xodimlar soni
2 700